Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

Myeloma Crowd Radio

Myeloma Crowd Radio


Follow This Show

Stay in the know about new episodes and updates.
Myeloma Crowd Radio brings you patient-led interviews of the world's top multiple myeloma researchers. Call in live at showtime to (347) 637-2631 ask questions and to learn about the latest innovation in simple terms patients can understand.

On-Demand Episodes

Natural killer cells are the body's way of eliminating cancerous cells. When a myeloma patient's immune system is too weak, the natural killer cells can't effectively do their job to eliminate myeloma. A study is now being done to test... more

Allogeneic stem cell transplant was the first ever immunotherapy available for mulitple myeloma patients. Dr. Matsui shares how the Johns Hopkins allo transplant procedure has significantly improved safety concerns. His research is... more

Dr. Martin Kaiser joins Myeloma Crowd Radio to share more about the latest advances in myeloma treatment in the United Kingdom and how the use of myeloma genomic data with thousands of patients in the UK is furthering new... more

The year 2018 promises to be an exciting one in multiple myeloma research. Learn what about key findings from the recent ASH conference in addition to what we can look forward to in the coming year. With the explosion of... more

Multiple myeloma treatment can cause "financial toxicity" for patients who are trying to pay for care that will give them optimal outcomes. Diahanna Valentine joins the Myeloma Crowd to discuss financial resources that are available to... more

Myeloma patients can't wait until blood-based "liquid biopsies" replace the dreaded bone marrow biopsy. Painful and intrusive, the bone marrow biopsy is today's "standard" of myeloma testing to determine levels of myeloma disease... more

Sugar molecules could act as a smoke screen for multiple myeloma cells, essentially hiding them from the immune system. The surface sugars, called sialic acids, can mark the cancer cells as ?self? cells, giving the immune system the... more

The recent meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA) occurred recently in May and June. There are a wealth of updates on up-and-coming therapies, use of combinations... more

Many patients are familiar with the monoclonal antibodies daratumumab and elotuzumab. These target a specific protein on the surface of myeloma cells. A new approach is in progress to target both a protein on the surface of myeloma... more

Can the genetics of myeloma or other clinical factors predict who will progress from early conditions like MGUS and smoldering myeloma to active myeloma? Dr. Elisabet Manasanch of the MD Anderson Cancer Center is hosting a study in... more
Show Extras